Compare Stocks: XTLB, KZIA, LGVN, and NXTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$15.83 +8.5%	$13.42	$4.86 ▼ $17.40	$26.01M	2.16	205,928 shs	68,862 shs
LGVN Longeveron	$6.98 -0.8%	$0.70	$4.75 ▼ $12.30	$222.36M	-0.31	233,898 shs	54,280 shs
NXTC NextCure	$6.30 +8.1%	$4.47	$1.55 ▼ $15.74	$22.75M	1.27	860,304 shs	24,652 shs
XTLB XTL Biopharmaceuticals	$2.53 -1.9%	$2.79	$2.01 ▼ $10.28	$5.56M	1.46	10,634 shs	2,597 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	+5.87%	+3.77%	+19.57%	+15.23%	+80.69%
LGVN Longeveron	+3.43%	-14.47%	+15.14%	-13.69%	-14.02%
NXTC NextCure	-1.35%	-14.01%	+13.87%	-8.91%	+11.69%
XTLB XTL Biopharmaceuticals	-0.77%	-13.42%	-8.35%	+4.88%	-85.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$15.83 +8.5%	$13.42	$4.86 ▼ $17.40	$26.01M	2.16	205,928 shs	68,862 shs
LGVN Longeveron	$6.98 -0.8%	$0.70	$4.75 ▼ $12.30	$222.36M	-0.31	233,898 shs	54,280 shs
NXTC NextCure	$6.30 +8.1%	$4.47	$1.55 ▼ $15.74	$22.75M	1.27	860,304 shs	24,652 shs
XTLB XTL Biopharmaceuticals	$2.53 -1.9%	$2.79	$2.01 ▼ $10.28	$5.56M	1.46	10,634 shs	2,597 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	+5.87%	+3.77%	+19.57%	+15.23%	+80.69%
LGVN Longeveron	+3.43%	-14.47%	+15.14%	-13.69%	-14.02%
NXTC NextCure	-1.35%	-14.01%	+13.87%	-8.91%	+11.69%
XTLB XTL Biopharmaceuticals	-0.77%	-13.42%	-8.35%	+4.88%	-85.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZIA Novogen	2.71	Moderate Buy	$26.33	66.31% Upside
LGVN Longeveron	2.00	Hold	$80.00	1,046.95% Upside
NXTC NextCure	2.25	Hold	$19.00	201.54% Upside
XTLB XTL Biopharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XTLB, KZIA, LGVN, and NXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
8/12/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	KZIA Novogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/15/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
7/9/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZIA Novogen	$42K	623.18	N/A	N/A	($5.34) per share	-2.97
LGVN Longeveron	$1.20M	185.30	N/A	N/A	$0.33 per share	21.14
NXTC NextCure	N/A	N/A	N/A	N/A	$3.36 per share	N/A
XTLB XTL Biopharmaceuticals	$450K	12.37	N/A	N/A	($0.12) per share	-21.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/4/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$0.99	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)
XTLB XTL Biopharmaceuticals	-$6.97M	-$0.64	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest XTLB, KZIA, LGVN, and NXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	N/A	KZIA Novogen	-$0.6455	N/A	N/A	N/A	$0.13 million	N/A
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$1.90	-$0.15	-$0.19	$0.33 million	$0.29 million
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A
6/30/2026	Q4 2025	XTLB XTL Biopharmaceuticals	N/A	-$0.10	N/A	-$0.10	N/A	($0.26) million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZIA Novogen	N/A	2.87	N/A
LGVN Longeveron	N/A	2.63	2.63
NXTC NextCure	N/A	3.47	3.47
XTLB XTL Biopharmaceuticals	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZIA Novogen	30.89%
LGVN Longeveron	10.01%
NXTC NextCure	42.65%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
KZIA Novogen	1.00%
LGVN Longeveron	7.42%
NXTC NextCure	11.90%
XTLB XTL Biopharmaceuticals	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZIA Novogen	12	1.65 million	1.64 million	No Data
LGVN Longeveron	20	31.88 million	29.52 million	Not Optionable
NXTC NextCure	90	3.61 million	3.18 million	No Data
XTLB XTL Biopharmaceuticals	N/A	2.20 million	1.57 million	Not Optionable

XTLB, KZIA, LGVN, and NXTC Headlines

Recent News About These Companies

XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above Fifty Day Moving Average - Here's What Happened

August 20, 2026 | americanbankingnews.com

XTL Biopharmaceuticals Ltd. Sponsored ADR

July 8, 2026 | cnn.com

XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-Hours

July 1, 2026 | nasdaq.com

XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform

June 30, 2026 | quiverquant.comQ

XTL Completed the Acquisition of Psyga Bio Ltd.

June 30, 2026 | globenewswire.com

XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026

June 23, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 23, 2026 | finanznachrichten.de

XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 22, 2026 | globenewswire.com

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

May 15, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd ADR XTLB

May 14, 2026 | morningstar.comM

XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation

May 3, 2026 | theglobeandmail.com

XTL Biopharmaceuticals Ltd.

May 1, 2026 | marketwatch.com

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

May 1, 2026 | theglobeandmail.com

XTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the table

May 1, 2026 | msn.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...

April 29, 2026 | markets.businessinsider.com

XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth

April 29, 2026 | msn.com

XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement

April 29, 2026 | quiverquant.comQ

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline

April 29, 2026 | tipranks.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

April 29, 2026 | globenewswire.com

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio Change

March 21, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, KZIA, LGVN, and NXTC Company Descriptions

Novogen NASDAQ:KZIA

$15.83 +1.23 (+8.45%)

As of 10:49 AM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Longeveron NASDAQ:LGVN

$6.98 -0.06 (-0.82%)

As of 10:48 AM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

NextCure NASDAQ:NXTC

$6.30 +0.47 (+8.08%)

As of 10:48 AM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

XTL Biopharmaceuticals NASDAQ:XTLB

$2.53 -0.05 (-1.94%)

As of 10:44 AM Eastern

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XTLB, KZIA, LGVN, and NXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XTLB, KZIA, LGVN, and NXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XTLB, KZIA, LGVN, and NXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, KZIA, LGVN, and NXTC Company Descriptions

Novogen NASDAQ:KZIA

Longeveron NASDAQ:LGVN

NextCure NASDAQ:NXTC

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XTLB, KZIA, LGVN, and NXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XTLB, KZIA, LGVN, and NXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XTLB, KZIA, LGVN, and NXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, KZIA, LGVN, and NXTC Company Descriptions

Novogen NASDAQ:KZIA

Longeveron NASDAQ:LGVN

NextCure NASDAQ:NXTC

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools